Role of PSMA-PET/MRI for diagnosis and follow-up of focal therapy of prostate cancer
Not Applicable
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00022363
- Lead Sponsor
- niversitätsmedizin Mannheim, Klinik für Urologie und Urochirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
Biopsy proven prostate cancer
- Serum PSA-level < 10ng/ml
- Gleason Score = 3 + 4
Exclusion Criteria
- mpMRI or PET contraindications
- contrast agent allergy
- Pacemaker, neurostimulator, insulin pump
- shards of metal
- dental implants
- other implants
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection rate of prostate cancer<br>Detection rate of nodal and distant metastasis<br>Detection rate of residual / recurrent cancers after treatment
- Secondary Outcome Measures
Name Time Method Detection rate of clinically significant prostate cancers<br>Comparison of imaging results between multiparametric MRI, PSMA-PET and the combination of both<br>Comparison of imaging and histopathological results with results of conventional imaging